AxoGen (AXGN) is a medical technology company dedicated to peripheral nerve repair.
AXGN's surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.
In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
AXGN provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally.
AxoGen, Inc. is headquartered in Alachua, Florida.
December 16, 2022
RegMed Investors’ (RMi) closing bell: sector extends losses as selling pressure continues
December 13, 2022
RegMed Investors’ (RMi) closing bell: indexes slow and some sector gains evaporate post CPI release
December 12, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector opened and closed higher as oversold were “recognized” in-front of CPI and Fed meeting report
December 1, 2022
RegMed Investors’ (RMi) closing bell: hitting the brakes as December begins
November 29, 2022
RegMed Investors’ (RMi) closing bell: the pendulum swung
November 28, 2022
RegMed Investors’ (RMi) closing bell: Being greedy when others are fearful is easier said than done
November 25, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector equities faltered Friday in a subdued trading session.
November 18, 2022
RegMed Investors’ (RMi) closing bell: this week the cell and gene therapy sector equities got “whacked’ on the knuckles, today it got a pat on the back!
November 15, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector gains held fast against PPI and Poland missile strike
November 15, 2022
RegMed Investors’ (RMi) pre-open: Monday’s whiplash leaves share pricing ready to move upward
35 companies, 1 interpreter!
Insight, foresight and recommendation
AxoGen, Inc. (AXGN) – January '18 opened at $27.95 with an upside of $28.05 on 2/1 while dropping to $27.40 on 2/16 ... since November of '17 appreciation has withstood mild drags to the downside ...
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.